Weekly Paclitaxel versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study | Zendy

Mohammed A. Osman | Zendy; Mohammad Sabry Elkady | Zendy; Khalid E. Nasr | Zendy

Open Access

Weekly Paclitaxel versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

Author(s) -

Mohammed A. Osman,

Mohammad Sabry Elkady,

Khalid E. Nasr

Publication year - 2016

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s38204

Subject(s) - paclitaxel , oncology , medicine , platinum , chemotherapy , biology , biochemistry , catalysis

Treatment of recurrent platinum-resistant ovarian and peritoneal cancers represents a therapeutic challenge. The aim of this Phase III prospective study was to compare the survival benefits, objective response rate, and toxicities among patients treated by weekly paclitaxel with those who underwent three-weekly paclitaxel in recurrent platinum-resistant ovarian and peritoneal cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research